title: Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
abstract: Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are emerging global health threats. Bedaquiline is a new antituberculous drug belonging to the diarylquinoline class that efficiently inhibits the adenosine triphosphate synthase enzyme of Mycobacterium tuberculosis. It is a bactericidal and long-acting drug. It inhibits both dormant as well as replicating bacterial sub-populations and thus shortens the duration of TB treatment. This drug has been approved by the Food and Drug Administration in December 2012 for the management of multidrug resistant-TB. The drug marks the introduction of a new addition to the TB armamentarium after four decades.
authors.affiliation: Department of Pharmacology, Mandya Institute of Medical Sciences, Mandya, Karnataka, India.
authors.forename: H
authors.initials: H
authors.lastname: Nagabushan
authors.forename: H S
authors.initials: HS
authors.lastname: Roopadevi
mesh_terms: D000995:Antitubercular Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D064687:Diarylquinolines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017277:Drug Approval; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000995:Antitubercular Agents; D064687:Diarylquinolines; C493870:bedaquiline